Fayerweather Charles Continues to Hold Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Fayerweather Charles held its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 2,143 shares of the medical equipment provider’s stock at the end of the second quarter. Fayerweather Charles’ holdings in Zimmer Biomet Holdings were worth $275,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of ZBH. Parkside Financial Bank & Trust raised its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares during the period. Parallel Advisors LLC raised its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the period. IHT Wealth Management LLC raised its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the period. Sandy Spring Bank raised its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares during the period. Finally, Ledyard National Bank raised its position in Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 110 shares during the period. 82.84% of the stock is owned by hedge funds and other institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 111.38 on Friday. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The stock has a market capitalization of $22.52 billion, a price-to-earnings ratio of 31.72 and a beta of 1.20. The firm’s 50-day moving average is $122.63 and its 200-day moving average is $121.15.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.02 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is 27.59%.

ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/19/fayerweather-charles-maintains-stake-in-zimmer-biomet-holdings-inc-nysezbh-updated-updated.html.

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus reissued a “hold” rating and issued a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Needham & Company LLC lifted their price target on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, April 28th. Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings currently has a consensus rating of “Hold” and an average target price of $136.90.

In related news, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit